Conventional Immunosuppression is Compatible with Costimulation Blockade‐Based, Mixed Chimerism Tolerance Induction
Andrew Adams(University of Minnesota), Christian P. Larsen(Emory University Hospital), Thomas R. Jones(University of New Mexico), Kenneth A. Newell(Unknown), Thomas C. Pearson(Emory Healthcare), Zhong Guo(University of Chicago), Matthew A. Williams(University of Utah), Ying Dong(Capital Medical University), Nozomu Shirasugi(Emory University), Jongwon Ha(Seoul National University), Megan M. Durham(Children’s Institute)
Cited by 23
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566